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Mutations in p53 are among the most frequent genetic alterations
detected in lung cancer and are acquired early in the development
of the disease (Bennett et al, 1993; Bennett, 1995). In non-small
cell lung cancer (NSCLC) about half of the tumours carry muta-
tions in the p53 gene (Takagi et al, 1998). The prevalent type of
mutation is G:C Õ T:A transversion which is related to DNA
adducts of benzo(a)pyrene from cigarette smoking (Greenblatt
et al, 1994; Denissenko et al, 1996). p53 plays an important role
in preserving genomic stability through controlling the cell cycle
checkpoints (Hartwell, 1992). Both human and mouse cells
homozygous for p53 mutations are genetically unstable and show
high rates of homologous recombination (Livingstone et al, 1992;
Yin et al, 1992; Mekeel et al, 1997). Other potential tumour
suppressor genes are localized on chromosomes 3p, 5q, 9p and 11p
(Kohno et al, 1999). It has been shown that deletions of chromo-
some 3p are early events in the development of the disease, and
such changes are often observed in lung tumours (Wistuba et al,
1997). The FHIT gene at 3p14.2 has been shown to be a target of
carcinogens in the tobacco smoke (Sozzi et al, 1997). The hMLH1
gene maps to 3p21.3 and a high frequency of loss of hetero-
zygosity (LOH) has been shown at this locus in lung cancer
(Benachenhou et al, 1998). A concordant LOH of hMLH1 locus
and the hMSH3 locus at 5q11–13 has been reported (Benachenhou
et al, 1998). Mutations in the mismatch repair genes (MMR) are
associated with a distinct molecular phenotype known as
microsatellite instability (MSI) (Eshleman and Markowitz 1996).
In lung cancer, the majority of studies have reported a low level
(<5%) of MSI (Benachenhou et al, 1998). However, studies have
shown that defects in DNA repair may be a predisposing factor in
lung cancer (Wei and Spitz, 1997). 
Lung cancer is characterized by multiple genetic changes
(Gazdar, 1994). A relationship between p53 mutations and 3p
deletions has been reported in lung cancer (Horio et al, 1993;
Burke et al, 1998; Kohno et al, 1999). The purpose of this study
was to explore the association between tobacco exposure, p53
mutations and concordant LOH at several loci harbouring
potential tumour suppressor genes involved in lung cancer. 
MATERIALS AND METHODS 
Tissue samples 
Surgically resected tumours and corresponding normal lung tissue
were obtained from 165 lung cancer patients. The majority of
tumours were at stage I according to international TNM staging.
Each tissue was snap-frozen after surgery and stored at –80˚C.
Prior to DNA isolation the tumour tissues were freeze-sectioned.
5–10 sections of each sample were stained with eosin and haema-
toxylin. Based on these slides, the tumours were trimmed to obtain
more than 70% tumour cells. Histological classification of
tumours was made according to guidelines made by the WHO
Histological Typing of Lung Tumours (WHO, 1981). A question-
naire was filled out for each patient by the treating physician,
including information on smoking habits. The characteristics of
the lung cancer patients are summarized in Table 1. 
Analysis of LOH using microsatellite markers 
17 polymorphic dinucleotide (CA) repeats representing regions
with known DNA repair genes or tumour suppressor genes were
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hMSH2-hMSH6 mismatch repair genes on chromosome
2p16–21. D3S1300 is mapped within the FHIT gene (3p14.2),
D3S1611 is internal to the hMLH1 gene (3p21) and D3S1612 is
closely linked to it. The hMSH3 gene is located near D5S431
marker at 5q11–13. hPMS2 is mapped near D7S531 locus (7p22).
The markers TP53 and D17S786 are linked to the p53 gene.
The other markers represent chromosomal regions often deleted
in lung cancer. The PCR methods and sequences of the pri-
mers except for D2S123 and D11S4181 are previously publi-
shed (Lindstedt et al, 1999). The primer sequences for the 2
markers are: D2S123, 5¢-GCCTGCCTTTAACAGTGCTA-3¢, 
5¢-AGGGGACTTTCCACCTATG-3¢; D11S4181,5¢-AGAGGC-
AGGAGAATCACTTG3¢,5¢-CACTAAACATCCAGCTCAA-A-3¢.
The map positions of the markers are based on the Human
Genetic Map available in various databases. DNA samples were
analysed for LOH by multiplex PCR and capillary electro-
phoresis as described (Canzian et al, 1996). To facilitate multi-
plexing, the size of the amplified product and the annealing
temperatures were considered. The oligonucleotides were
labelled fluorescently with one of the 3 dyes (6-FAM, TET, HEX;
Applied Biosystems) and the fourth dye TAMRA was reserved
for the size standard. After collection, data were analysed using
the Gene Scan software (Applied Biosystems) and allelic imbal-
ance was determined and LOH was defined as at least 50% loss
of one allele in the tumour tissue after correction for the non-
tumour tissue. 
Determination of PAH-DNA adducts 
The PAH-DNA adducts were analysed by the 32P-postlabelling
method as described previously and published (Mollerup et al,
1999). 
Analysis of p53 mutations 
The  p53 mutation analysis was performed using a modified
single-strand conformation polymorphism (SSCP) procedure and
direct sequencing as described (Kure et al, 1996; Skaug et al,
2000). 
Statistical methods 
The hypothesis of independence in LOH at the 4 most involved
loci was tested using likelihood ratio test with correction for con-
tinuity. Logistic regression analysis (SPSS v. 10) was used to iden-
tify important variables predicting LOH and to calculate adjusted
P values. The following variables were included in the model: p53
mutational status, smoking status, gender, age and histological
types. p53 mutational status and histological types were the only
significant parameters predicting LOH status at most of the loci.
Since the number of non-smoker patients was low in this study, the
association between smoking status and LOH status was analysed
using Fishers exact test. The relationship between PAH adduct
levels and LOH status was analysed by Wilcoxon rank sum test.
The StatXact version 4 program was used for trend analysis. 
RESULTS 
Paired tumour/normal DNA samples from 165 NSCLC patients
(Table 1) were examined for allelic imbalance at 17 polymorphic
microsatellite markers in 7 different chromosomes. High LOH
frequencies (about 50%) were observed with 3p, 5q, 9p and 17p
markers, moderate LOH at 11p15, and low frequencies at 7p and 2p
(Table 2). There was a significant correlation between deletions in
markers at 3p, 5q, 9p, 11p and 17p loci (data not shown). The
concordant LOH at the 4 most deleted loci 3p21, 5q11–13, 9p21 and
17p13 based on data from the markers D3S1611-D3S1612, D5S431,
D9S157 and TP53-D17S786, respectively, was further examined. 83
cases were informative for all these 4 loci; 14 cases were deleted at
all 4 loci, 21 deleted at 3 loci, 14 at 2 loci, 9 at one locus, and 25 cases
had retained heterozygosity at all 4 loci. The corresponding expected
frequencies based on independence would be 4.5, 19.3, 31.1, 22.2
and 5.9 cases. This difference in the observed and expected frequen-
cies of concordant LOH at the 4 loci was statistically significant and
the possibility that these deletions may have occurred independently
should be rejected (P = 0.03 ´ 10–5, likelihood ratio test with correc-
tion for continuity). Similar results were obtained using other
markers at 3p, 5q and 17p. Of 115 cases informative for hMLH1
(D3S1611-D3S1612) and hMSH3 (D5S431), 47 (41%) were deleted
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Table 1 Characteristics of lung cancer patients 
Parameter No. (%) Mean (95% CI)
Total 165 
Male 122 (73.9) 
Female 43 (26.1) 
Histological subtype 
Adenocarcinoma 69 (41.8) 
Squamous cell carcinoma 68 (41.2) 
Othera 28 (17.0) 
Age 62.1 (60.4–63.9) 
Smoking history 
Smokers 147 (89.1) 
Cigarettes per day 15.6 (14.4–16.7) 
Pack-years 30.7 (28.1–33.4) 
Years of smoking 39.6 (37.4–41.7) 
Non-smokersb 15 (9.1) 
Unknown 3 (1.8) 
CI, confidence interval; aOther includes unknown, large cell and small cell
(2 cases) carcinomas; bNot smoked for the past 20 years. 
Table 2 Frequency of LOH at different microsatellite loci in lung cancer
patients 
Microsatellite Informative LOHa
marker cases n (%) n (%) 
D2S123 127 (77.4) 19 (15.0) 
D2S391 123 (75.0) 15 (12.2) 
D3S1611 109 (66.1) 51 (46.8) 
D3S1612 117 (71.3) 55 (47.0) 
D3S966 128 (77.6) 61 (47.7) 
D3S1289 144 (87.3) 66 (45.8) 
D3S1300 136 (82.4) 64 (47.1) 
D5S1968 126 (76.8) 56 (44.4) 
D5S2089 134 (81.7) 56 (41.8) 
D5S431 131 (79.4) 60 (45.8) 
D5S495 109 (66.5) 45 (41.3) 
D7S531 134 (81.2) 18 (13.4) 
D9S157 136 (82.9) 65 (47.8) 
D11S4181 124 (79.5) 45 (36.2) 
D17S799 123 (75.0) 61 (49.6) 
D17S786 122 (73.9) 62 (50.8) 
TP53 73 (44.5) 33 (45.2) 
aLOH = no. of cases with deletions/no. of informative cases. at both loci. However, this was not specific for these 2 loci since
similar frequencies were found at other loci investigated. 
The p53 mutations were found in 86 (52%) of the 165 tumours
analysed (Kure et al, 1996; Skaug et al, 2000). Using logistic
regression and adjusting for other variables there was a significant
association between the presence of p53 mutations and occurrence
of LOH at 3p, 5q, 9p, 11p and 17p (Table 3). Similar results were
also obtained when smoking status was replaced by smoking years
or pack-years in the logistic models. Of the 14 cases with concord-
ant LOH at the 4 most deleted regions (see above), 12 (85.7%) had
mutations in the p53 gene. The corresponding frequency of muta-
tions in the 25 tumours without LOH in these loci was only 2 (8%)
(P < 0.0001, Fishers exact test). There was also a significant corre-
lation between the frequency of p53 mutations and the number of
loci deleted (Figure 1, P < 0.0001 trend test). Of 47 cases deleted
in both hMLH1 and hMSH3 loci, 37 (79%) had p53 mutations
whereas only 11 (22%) of the 49 cases without LOH were mutated
in p53 (P < 0.0001, Fisher exact test). The LOH data were also
analysed with respect to p53 mutational types and positions
without any particular findings. 
The frequency of LOH was significantly lower in non-smokers
as compared to smokers for the hMLH1 locus, D3S1300 (FHIT),
D5S431 (hMSH3), and D9S157 using table analysis and Fishers
exact test (Table 4). Using logistic regression and adjusting for p53
mutational status, histological types, age and gender only the
D9S157 marker gave significant association. Since the number of
non-smokers is low and p53 mutations are nearly absent among
non-smoking patients, the last method is less reliable. Tumours
deleted in the hMLH1 locus showed higher PAH-DNA adduct
levels (P = 0.078, Wilcoxon rank test) and there were more
tumours with LOH in this locus in the upper adduct tertile (³12.36
adducts/108 nucleotides) than in the lower tertile group (≤6.67
adducts/108 nucleotides, P = 0.06, Fisher’s exact test). Other loci
on 3p showed similar tendency, but the statistics were weaker. 
The frequency of LOH was significantly higher in squamous
cell carcinomas compared to adenocarcinomas for several loci
after adjusting for p53 mutational status, smoking status, gender
and age (Table 5). Similar results were seen when smoking years
and pack-years replaced smoking status in the logistic models.
Among the 14 tumours with LOH at all the 4 most involved loci, 9
(64.3%) were squamous cell carcinomas and 3 (21.4%) were
adenocarcinomas. 
DISCUSSION 
Lung tumours harbour several genetic abnormalities including p53
mutations and loss of several chromosomal regions. In this study
we have examined possible interactions between several genetic
alterations in the tumours, particularly at loci with potential
tumour suppressor genes. 
Analysis of the sequence of abnormalities in lung cancer has
shown that deletions in the 3p region are early events and precede
deletions in 9p, 17p (TP53 locus) and 5q (Wistuba et al, 1999).
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Figure 1 Correlation between incidence of p53 mutations and number of
loci deleted in tumours informative for all the 4 loci, 3p21, 5q11–13, 9p21
and 17p13. Figures in ( ) indicate no. of informative cases. Trend test:
P = 0.0001 
Table 3 Frequencies of LOH at individual locus in relation to mutational status of the p53 gene 
p53 gene 2p16–21 3p21.3 3p14.2  5q11–13 5q21 7p22 9p21 11p15 17p13
status (D2S123– (D31611– (D3S1300) (D5S431) (D5S495) (D7S531) (D9S157) (D11S4181) (TP53– 
D2S391)a D3S1612)a D17S786)a
Mutated 11/72 52/76 44/71 44/66 31/56 10/72 48/74 34/65 51/75 
Normal 5/71 20/69 20/65 16/65 14/53 8/62 17/62 11/59 19/67 
Pb NS 0.001 0.03 0.001 0.04 NS 0.001 0.003 0.002 
aLOH at one or both markers. bP-values based on logistic regression adjusting for smoking status, gender, age and histological types. NS – not significant. 
Table 4 Frequency of LOH in smokers and non-smokers 
Chromosome 2p16–21 3p21.3 3p14.2 5q11–13  5q21 7p22 9p21 11p15 7p13 
(D2S123– (D31611– (D3S1300) (D5S431) (D5S495) (D7S531) (D9S157) (D11S4181) (TP53–
D2S391)a D3S1612)a D17S786)a
Smokersb 25/134 70/129 63/124 59/115 43/99 16/121 63/121 38/105 65/129 
Non-smokersb 0/15 2/14 1/10 1/12 2/7 2/11 1/14 3/14 4/11 
P (Fishers exact  0.08 0.005 0.02 0.005 NS NS 0.001 NS NS 
test)
aLOH at one or both markers; NS – not significant. Further deletion mapping of the 3p region has revealed chromo-
somal regions 3p21 and 3p14 to be most frequently deleted in
many cancer types including NSCLC (Mitsudomi et al, 1996;
Todd et al, 1997; Benachenhou et al, 1998;  Nelson et al, 1998).
The relationship between allelic losses at the various loci, may
indicate an interaction between various gene(s) in these loci during
the process of clonal selection. 
The high frequency of deletions found at the hMLH1 and
hMSH3 loci may indicate a possible role for these loci in NSCLC.
A possible interdependence of LOH at these loci has been indi-
cated (Benachenhou et al, 1998). This study confirmed concom-
itant LOH in cases informative for both loci. However, a similar
concomitant LOH frequency was also found when other frequently
affected regions were investigated. Similar LOH frequencies were
also observed for other markers within the 3p region and 5q region
indicating an interaction between several genes, not specifically on
3p21 and 5q11–13. The unexpectedly high number of tumours
without apparent LOH at the 4 most involved loci at 3p21,
5q11–13, 9p21 and 17p13 (25 cases against the expected 5.9 cases)
may indicate that specific mechanisms are involved, resulting in
frequent deletions in all these loci. DNA repair genes like hMLH1
and hMSH3, and the p53 gene may be involved in these mecha-
nisms. Deficiencies in MMR genes are associated with several
cancers often resulting in MSI in tumours (Lengauer et al, 1997).
MSI in lung cancer occurs at a low frequency (Benachenhou et al,
1998). However, MMR proteins are involved in a variety of other
cellular processes such as homologous recombination (de Wind
et al, 1995), mediation of the G2 checkpoint (Meyers et al, 1997;
Davis et al, 1998), the signalling pathway and transcription-
coupled nucleotide excision repair (Mellon et al, 1996). Gene-
dosage effects and reduced expression of MMR proteins have been
suggested as risk factors (Wei et al, 1996, 1998; Benachenhou et
al, 1998). Other DNA repair genes such as hRad51 and hOGG1
may also be involved (Buchhop et al, 1997; Chevillard et al, 1998).
Several genes localized at the other frequently deleted loci such as
FHIT (3p14.2), APC (5q21), p16 (9p21) and other genes at 17p
may also interact with each other. Correlations between p53 muta-
tions and LOH at FHIT locus and 9p have also been reported in
lung tumours by others (Marchetti et al, 1998; Kohno et al, 1999).
The low rate of allelic losses (12–15%) affecting hMSH2-hMSH6
(2p21–16) and hPMS2 (7p22) loci is consistent with previous
reports and may reflect the base line LOH in cancer cells
(Benachenhou et al, 1998, 1999). This may also indicate that dele-
tion may not be an inactivating mechanism for these genes or these
genes may play a minor role in lung cancer. 
The p53 gene was mutated in 52% of NSCLC cases. This fre-
quency is consistent with the average incidence reported in NSCLC
(Greenblatt et al, 1994; Hollstein et al, 1994). A significantly higher
number of tumours with LOH had p53 mutations compared to
tumours without LOH. Logistic regression analysis revealed that p53
mutational status was the most significant variable for explaining
LOH at most of the examined loci. The highly significant trend
(P<0.0001, trend test) toward increased frequency of p53 mutations
with the higher number of loci deleted, may further support a rela-
tionship between these two types of genetic alterations. Among
samples with concordant LOH at the 4 most deleted loci all 12 
samples with p53 mutations had mutations in reported hotspot codons
(Walker et al, 1999). Hotspot somatic mutations in cancers may repre-
sent protein alterations which provide a selective growth advantage to
the cell. Genomic instability in a subset of non-smoking lung cancer
patients has been related to mutations in the p53 gene (Pellegrini et al,
1999). Genomic instability induced by p53 may arise through
abnormal cell cycle check points (Hartwell, 1992). Considering the
involvement of both p53 and MMR genes in cell cycle, an interaction
between them in maintaining genomic stability may seem reasonable.
However, no correlation between MSI and p53 mutations has been
found in NSCLC (Caligo et al, 1998). Other pathways such as recom-
bination have also been reported to be involved in induction of LOH
in normal human cells (Gupta et al, 1997) and loss of both alleles of
p53 in a primary human glioblastoma tumour and cell line (Albertoni
et al, 1998). 
For all loci examined (except 7p), there was a clear trend of
higher occurrence of LOH in smokers than non-smokers. While
number of cases with LOH was significantly lower among non-
smokers in both regions of 3p (3p 14.2 and 3p21), this was only
significant for the 5q11–13 (hMSH3 locus) locus on chromo-
some 5q. Despite the low number of non-smoking cases, this
may indicate a possible association between smoking and occur-
rence of LOH. The differences in association of LOH with the
smoking status may suggest that the genetic loci may differ in
their sensitivity to the mutagenic effects of carcinogens. As-
sociations between cigarette smoking and FHIT gene (3p14.2)
alterations have been reported (Sozzi et al, 1997; Tomizawa et al,
1998). Deletions within the LOH11B locus on 11p have also been
associated with high cigarette consumption (Schreiber et al,
1997). Significantly higher p53 mutations in tumours and PAH-
DNA adduct levels in lung tissue are observed in smoking than
non-smoking lung cancer patients (Ryberg et al, 1994a, 1994b).
The higher frequency of tumours with LOH in 3p21.3 locus in
the upper adduct tertile may indicate a higher sensitivity of this
locus to tobacco carcinogens. An association of increased 3p21
LOH with increasing PAH-DNA adducts in squamous cell carci-
nomas of the lung has recently been reported (Hirao et al, 2000)
and Wu et al, (1998) demonstrated a dose–response relationship
between BPDE exposure and 3p21.3 (hMLH1 region) aberra-
tions in lymphocytes from lung cancer patients. 
Adenocarcinoma and squamous cell carcinoma are the two
major histological types found in NSCLC. This study showed that
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Table 5 Frequencies of LOH at individual locus in relation to the two major histological types 
Histological 2p16–21 3p21.3 3p14.2  5q11–13 5q21 7p22 9p21 11p15 17p13
subtype (D2S123– (D31611– (D3S1300) (D5S431) (D5S495) (D7S531) (D9S157) (D11S4181) (TP53–
D2S391)a D3S1612)a D17S786)a
Adenocarcinoma 8/60 22/59 20/53 17/55 11/46 6/56 26/58 19/55 27/60 
Squamous cell 3/61 40/62 35/62 33/53  23/42 8/54 29/53 19/46 34/60 
Pb NS 0.05 0.08 0.03 0.02 NS NS NS 0.04 
aLOH at one or both markers. bP-values based on logistic regression adjusting for p53 mutational status, smoking status, age and gender. NS – not significant. allelic deletions were more frequent in squamous cell carcinomas
for most loci. After adjusting for p53 mutational status, smoking,
gender and age the difference between the two subtypes became
significant for the 3p, 5q and 17p regions. Different pattern of
genetic changes have previously been reported for the 2 histo-
logical types (Sato et al, 1994). We have also found a significantly
higher frequency of p53 mutations in squamous cell carcinomas
than adenocarcinomas (Kure et al, 1996; Skaug et al, 2000). The
development of different histological types of lung tumours has
been suggested to reflect a dose effect of tobacco carcinogens.
More centrally located cells of the airways giving rise to squamous
cell carcinomas are exposed to a greater carcinogen concentration
than more distal cells giving rise to the more peripherally located
adenocarcinomas (Burke et al, 1998). 
Our data indicate that LOH at 3p, 5q, 9p, 11p and 17p regions,
often affected in NSCLC, are interdependent and highly associated
with mutated p53 gene. Compounds in the tobacco smoke in
addition to clonal selection may be the driving force in these
alterations. 
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